Vanguard crLyme vaccine, introduced to the market in January 2016, is the first and only multivalent recombinant Lyme vaccine to aid in the prevention of clinical disease and
subclinical arthritis associated with Borrelia burgdorferi, the causative agent of Lyme disease in dogs.
Lyme $ 44 For the vaccination of healthy dogs as an aid in the prevention of clinical disease and
subclinical arthritis associated with Borrelia burgdorferi.
Additionally, dogs with Lyme disease frequently develop
subclinical arthritis and inflammation that is not readily apparent during a routine examination.